Iovance Biotherapeutics, Inc.
IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candiā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.55
Price+4.08%
$0.10
1Y
Price
Market Cap
$922.728m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-15079.0%
EBITDA Margin-15800.8%
Net Profit Margin-17685.3%
Free Cash Flow MarginRevenue
$212.678m
+60.1%
1y CAGR+20.0%
3y CAGR+15.0%
5y CAGREarnings
-$375.364m
-1.3%
1y CAGR-11.4%
3y CAGR-15.4%
5y CAGREPS
-$1.24
+4.8%
1y CAGR+4.4%
3y CAGR-0.5%
5y CAGRBook Value
$767.865m
$966.740m
Assets$198.875m
Liabilities$53.719m
DebtDebt to Assets
5.6%
-0.2x
Debt to EBITDAFree Cash Flow
-$347.501m
-5.5%
1y CAGR-15.3%
3y CAGR-12.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company